Trial reportEye (London, England)2025
Changes in accommodation and vergence parameters with topical use of 0.025% and 0.05% atropine in myopes aged between 7 and 17 years.
Trial report in Eye (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dose-Dependent Effects of Atropine on Accommodative and Binocular Visual Function for Myopia Control in Children: A Systematic Review and Meta-Analysis.Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists) · 2026Pooled it
- Ocular Alignment and Strabismus-Related Findings Associated with Low-Dose Atropine for Myopia Control in Children: A Structured Narrative Review.Children (Basel, Switzerland) · 2026Review
- Clinical Evaluation of an Affordable Handheld Wavefront Autorefractor in an Adult Population in a Low-Resource Setting in the Amazonas.Vision (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the vergence and accommodation parameters of myopic children in the use of 0.025% and 0.05% atropine.
methodsIn total, 34 schoolchildren aged between 7 and 17 years were randomly divided into 2 groups: atropine 0.025% (n = 18) and atropine 0.05% (n = 16). The authors evaluated the parameters of accommodation and vergence before (baseline) and after the instillation of 1 drop of medication for 14 nights, on the 15th day in the morning. The accommodative parameters were near point of accommodation (NPA), accommodation amplitude (AA), negative relative accommodation (NRA), positive relative accommodation (PRA), accommodative facility (AF), accommodative lag (AL), and pupillary diameter. The vergence parameters were near point of convergence (NPC), accommodative convergence/accommodation (AC/A) ratio, positive fusional vergence (PFV), and negative fusional vergence (NFV).
resultsThere were significant changes in the accommodative parameters: NPA from 5.85 ± 1.75 cm to 11.33 ± 4.58 cm (atropine 0.025%) and from 5.23 ± 1.31 to 14.94 ± 9.36 cm (atropine 0.05%); reduction of AA from 18.58 ± 5.62D to 11.07 ± 6.99D (atropine 0.025%) and from 20.23 ± 5.11 to 9.40 ± 5.32D (atropine 0.05%); reduction of PRA in absolute terms (modulus) from -3.72 ± 1.90 to -2.12 ± 0.79 and from -4.31 ± 1.88 to -2.02 ± 0.98 (atropine 0.05%); reduction of AF from 10.56 ± 3.50 cpm to 5.00 ± 5.59 cpm (atropine 0.025%) and from 11.56 ± 2.16 to 1.94 ± 3.82 cpm (atropine 0.05%); and increase in pupillary diameter from 4.16 ± 0.90 mm to 5.44 ± 0.97 mm (atropine 0.025%) and from 4.04 ± 0.50 mm to 6.69 ± 0.62 mm (atropine 0.05%). In the vergence parameters, only the Near PFV with 0.025% atropine and changes in Far PFV with both 0.025% and 0.05% atropine showed significant differences compared to baseline.
conclusionsUnder the conditions of this study, the use of atropine at concentrations of 0.025% and 0.05% induced significant disturbances in the accommodative system, causing visual discomfort.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.